M
M. Argyropoulou
Researcher at National and Kapodistrian University of Athens
Publications - 5
Citations - 236
M. Argyropoulou is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Hidradenitis suppurativa & Adalimumab. The author has an hindex of 4, co-authored 5 publications receiving 190 citations.
Papers
More filters
Journal ArticleDOI
Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus.
Fotini B. Karassa,John P. A. Ioannidis,Kyriaki A. Boki,Giota Touloumi,M. Argyropoulou,Kyriakos A Strigaris,Haralampos M. Moutsopoulos +6 more
TL;DR: Among patients with SLE who have Neuropsychiatric disease, prior neuropsychiatric events and the antiphospholipid syndrome increase the risk of adverse outcomes.
Journal ArticleDOI
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
Theodora Kanni,M. Argyropoulou,Themistoklis N. Spyridopoulos,Aikaterini Pistiki,Michael Stecher,Charles A. Dinarello,John Simard,Evangelos J. Giamarellos-Bourboulis +7 more
TL;DR: MABp1 is a promising treatment for patients with hidradenitis suppurativa not eligible for adalimumab, a true human antibody targeting IL-1α with suggested mechanisms of action of inhibition of neovascularization and modulation of the production of IL-8 and hBD-2.
Journal ArticleDOI
Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab.
Evangelos J. Giamarellos-Bourboulis,M. Argyropoulou,Theodora Kanni,Themistoklis N. Spyridopoulos,I. Otto,O. Zenker,R. Guo,N. Riedemann +7 more
TL;DR: Circulating concentrations of the split complement factor C5a are significantly increased in hidradenitis suppurativa (HS)1 and IFX-1 is a monoclonal IgG4 kappa antibody that selectively binds to C5A and blocks its biological activity.
Journal ArticleDOI
Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
M. Argyropoulou,Theodora Kanni,Miltiades Kyprianou,N. Melachroinopoulos,Evangelos J. Giamarellos-Bourboulis +4 more
TL;DR: The introduction of adalimumab in the management of hidradenitis suppurativa raises questions regarding the cost‐efficacy of treatment.
Journal ArticleDOI
MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period.
Theodora Kanni,M. Argyropoulou,Charles A. Dinarello,J. Simard,Evangelos J. Giamarellos-Bourboulis +4 more
TL;DR: Results support the use of bermekimab as treatment alternative for patients non-eligible or non-responding to adalimumab.